Tag Archives: PBS

Botox listed on PBS from September

Botox (botulinum toxin type A) injection is now listed on the Pharmaceutical Benefits Scheme (PBS) for moderate-to-severe lower-limb spasticity following an acute event, such as stroke, traumatic brain injury and spinal cord injury. The PBS listing is seen to be an important development for survivors of neurological events who are …

Read More »

Australia risks falling behind in melanoma prevention

Melanoma Institute Australia is urging the federal government to undertake a timely and efficient review of an effective treatment for preventing the deadly spread of melanoma. The request follows the government announcement that the immunotherapy drug Nivolumab’s listing on the PBS had been deferred for further consideration. Nivolumab was one of …

Read More »

Asthma treatment option for PBS reimbursement

Since August 1, new once-daily asthma treatment option Arnuity Ellipta is being reimbursed on the PBS, according to GSK Australia. The listing provides “affordable access to another treatment option for suitable asthma patients aged 12 years and over”. “This new once-daily inhaler adds to the treatment options available to patients, …

Read More »

NPSA defends value of CSO wholesalers role

The National Pharmaceutical Services Association used the Pharmacy Guild’s 2019 Pharmacy WA Forum in Perth to “dispel myths and present facts” about the work of CSO wholesalers. The NPSA said that for 6.5 per cent of total PBS spend, CSO wholesalers uphold a commitment to Australian patients on behalf of …

Read More »

Approval for testosterone replacement gel on PBS

Testosterone replacement therapy Testavan has been listed on the PBS. Described as a “novel, hands-free, transdermal gel therapy”, Testavan has been available since August 1 for the estimated one in 500 organically hypogonadal men who meet reimbursement criteria. The hypogonadal men are confirmed testosterone deficient by clinical features and biochemical …

Read More »

Cheaper medication for cancer added to PBS

Four medicines that treat cancer and inflammatory disease have been added to the Pharmaceutical Benefits Scheme (PBS) at a cost of $56 million. The medicines to be extended or listed on the Pharmaceutical Benefits Scheme treat brain tumours, leukaemia, and inflammatory disease of the large blood vessels, Health Minister Greg …

Read More »

More patient input in PBS advocated

Australian patients should be given a greater say in which medicines receive government reimbursement, according to the ‘Broadening the Evidence’ report launched this week. Patient advocacy organisations, government representatives and patients themselves gathered in Sydney this week at the launch of the report, commissioned by Bristol-Myers Squibb (BMS) Australia The …

Read More »

Health Minister gets Biosimilar Week underway

The Official opening of Biosimilar Week, running from April 29 to May 3 featured a statement on the role of biosimilar medicines in a sustainable health system by Health Minister Greg Hunt. Mr Hunt began by welcoming delegates to the Generic and Biosimilar Medicines Association (GBMA), Biosimilar Grants and Biosimilar …

Read More »

Guild’s budget breakdown

In the federal budget edition of Forefront, the Pharmacy Guild has welcomed confirmation that the government, if re-elected, will provide $245 million over five years to improve consumer access to medicines and support community pharmacies. The funding includes: $215 million over three years from 2020-21 to provide additional remuneration to …

Read More »